Trever G Bivona MD
Assistant Professor, Medicine, University of California, San Francisco, School of Medicine
Join to View Full Profile
1600 Divisadero Street 4th floorBox 1674San Francisco, CA 94115
Phone+1 415-353-7160
Dr. Bivona is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2007 - 2011
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2005 - 2007
New York University School of MedicineClass of 2005
Certifications & Licensure
CA State Medical License 2012 - 2025
NY State Medical License 2007 - 2012
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Publications & Presentations
PubMed
- Condensates as a culprit in RAS activation and inhibitor resistance.Hannah C Bergo, Logan B Leak, Trever G Bivona
Cancer Research. 2025-03-07 - 1 citationsAuthor Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01 - Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping...Matthew S Lara, Jonathan W Riess, Jonathan W Goldman, Fei Jiang, Trever G Bivona
Clinical Lung Cancer. 2024-12-01
Journal Articles
- Aurora Kinase A Drives the Evolution of Resistance to Third-Generation EGFR Inhibitors in Lung CancerVictoria E Wang, Collin M Blakely, Trever G Bivona, Andrei Goga, Nature
- Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationJulia K Rotow, Trever G Bivona, Collin M Blakely, Clinical Lung Cancer
- RAS Nucleotide Cycling Underlies the SHP2 Phosphatase Dependence of Mutant BRAF-, NF1- and RAS-Driven CancersTrever Bivona, MD, Nature
Authored Content
- Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient with a MET Exon 14 Skipping MutationNovember 2018
Press Mentions
Damon Runyon Cancer Research Foundation Awards over $4.1 Million to Exceptional Early-Career ScientistsJuly 28th, 2022- Damon Runyon Cancer Research Foundation Awards $4.8 Million to Rising InvestigatorsJuly 15th, 2021
- Novel Structure Found in Tumor Cells May Open Door to New Kinds of Cancer TherapiesMay 11th, 2021
- Join now to see all
Grant Support
- Dissecting the role and mechanism of EML4-ALK condensates in oncogenic signaling and tumor growthUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2023–2028
- Bay Area Cancer Target Discovery and DevelopmentUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2027
- Bay Area Cancer Target Discovery and DevelopmentUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2027
- Bay Area Cancer Target Discovery and DevelopmentUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2027
- Bay Area Cancer Target Discovery and DevelopmentUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2027
- Bay Area Cancer Target Discovery and DevelopmentUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2022–2027
- BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2027
- BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2027
- BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2027
- BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2027
- BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2027
- BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2027
- BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2027
- BAY AREA & ANDERSON TEAM AGAINST ACQUIRED RESISTANCE - U54 PROGRAM (BAATAAR-UP)UNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2027
- UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2021–2026
- UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2021–2026
- UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2021–2026
- UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2021–2026
- UCSF Paul Calabresi K12 Career Development Program in Clinical OncologyUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2021–2026
- Characterization of YAP as a rational companion target in lung cancerUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2026
- Characterization of YAP as a rational companion target in lung cancerUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2026
- Stress responses drive resistance and shape tumor evolution in EGFR mutant lung cancerUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
